nodes	percent_of_prediction	percent_of_DWPC	metapath
Lithium—IMPA2—respiratory system—chronic obstructive pulmonary disease	0.0219	0.106	CbGeAlD
Lithium—GSK3B—respiratory system—chronic obstructive pulmonary disease	0.0215	0.104	CbGeAlD
Lithium—GSK3B—connective tissue—chronic obstructive pulmonary disease	0.0189	0.0912	CbGeAlD
Lithium—IMPA2—bronchus—chronic obstructive pulmonary disease	0.018	0.0869	CbGeAlD
Lithium—GSK3B—smooth muscle tissue—chronic obstructive pulmonary disease	0.0173	0.0834	CbGeAlD
Lithium—GSK3A—connective tissue—chronic obstructive pulmonary disease	0.0165	0.0793	CbGeAlD
Lithium—IMPA2—trachea—chronic obstructive pulmonary disease	0.0162	0.078	CbGeAlD
Lithium—GSK3A—bronchus—chronic obstructive pulmonary disease	0.0154	0.0741	CbGeAlD
Lithium—GSK3A—smooth muscle tissue—chronic obstructive pulmonary disease	0.0151	0.0725	CbGeAlD
Lithium—GSK3A—trachea—chronic obstructive pulmonary disease	0.0138	0.0666	CbGeAlD
Lithium—IMPA2—lung—chronic obstructive pulmonary disease	0.0116	0.0561	CbGeAlD
Lithium—GSK3B—lung—chronic obstructive pulmonary disease	0.0114	0.055	CbGeAlD
Lithium—GSK3A—lung—chronic obstructive pulmonary disease	0.00993	0.0478	CbGeAlD
Lithium—Optic neuritis—Prednisolone—chronic obstructive pulmonary disease	0.0025	0.00592	CcSEcCtD
Lithium—Dysgeusia—Roflumilast—chronic obstructive pulmonary disease	0.00239	0.00567	CcSEcCtD
Lithium—Dehydration—Tiotropium—chronic obstructive pulmonary disease	0.00237	0.00562	CcSEcCtD
Lithium—Hypertonia—Salbutamol—chronic obstructive pulmonary disease	0.00235	0.00556	CcSEcCtD
Lithium—Dry skin—Tiotropium—chronic obstructive pulmonary disease	0.00234	0.00554	CcSEcCtD
Lithium—Tremor—Roflumilast—chronic obstructive pulmonary disease	0.00229	0.00542	CcSEcCtD
Lithium—Angioedema—Roflumilast—chronic obstructive pulmonary disease	0.00223	0.00529	CcSEcCtD
Lithium—Vertigo—Roflumilast—chronic obstructive pulmonary disease	0.00219	0.0052	CcSEcCtD
Lithium—Thirst—Montelukast—chronic obstructive pulmonary disease	0.00212	0.00502	CcSEcCtD
Lithium—Hyperglycaemia—Aminophylline—chronic obstructive pulmonary disease	0.00211	0.005	CcSEcCtD
Lithium—Discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00205	0.00487	CcSEcCtD
Lithium—Hyperglycaemia—Tiotropium—chronic obstructive pulmonary disease	0.00199	0.00471	CcSEcCtD
Lithium—Dehydration—Formoterol—chronic obstructive pulmonary disease	0.00191	0.00454	CcSEcCtD
Lithium—Dehydration—Arformoterol—chronic obstructive pulmonary disease	0.00191	0.00454	CcSEcCtD
Lithium—Dry skin—Arformoterol—chronic obstructive pulmonary disease	0.00189	0.00447	CcSEcCtD
Lithium—Dry skin—Formoterol—chronic obstructive pulmonary disease	0.00189	0.00447	CcSEcCtD
Lithium—Ataxia—Salbutamol—chronic obstructive pulmonary disease	0.00183	0.00433	CcSEcCtD
Lithium—Gastritis—Arformoterol—chronic obstructive pulmonary disease	0.00182	0.00432	CcSEcCtD
Lithium—Gastritis—Formoterol—chronic obstructive pulmonary disease	0.00182	0.00432	CcSEcCtD
Lithium—Musculoskeletal discomfort—Roflumilast—chronic obstructive pulmonary disease	0.00182	0.0043	CcSEcCtD
Lithium—Optic neuritis—Prednisone—chronic obstructive pulmonary disease	0.00181	0.0043	CcSEcCtD
Lithium—Dyspepsia—Roflumilast—chronic obstructive pulmonary disease	0.00175	0.00416	CcSEcCtD
Lithium—Hypothyroidism—Prednisone—chronic obstructive pulmonary disease	0.00174	0.00412	CcSEcCtD
Lithium—Decreased appetite—Roflumilast—chronic obstructive pulmonary disease	0.00173	0.00411	CcSEcCtD
Lithium—Fatigue—Roflumilast—chronic obstructive pulmonary disease	0.00172	0.00407	CcSEcCtD
Lithium—Arrhythmia—Aminophylline—chronic obstructive pulmonary disease	0.00167	0.00396	CcSEcCtD
Lithium—Alopecia—Aminophylline—chronic obstructive pulmonary disease	0.00165	0.00392	CcSEcCtD
Lithium—Feeling abnormal—Roflumilast—chronic obstructive pulmonary disease	0.00164	0.00389	CcSEcCtD
Lithium—Gastrointestinal pain—Roflumilast—chronic obstructive pulmonary disease	0.00163	0.00386	CcSEcCtD
Lithium—Hyperglycaemia—Formoterol—chronic obstructive pulmonary disease	0.0016	0.0038	CcSEcCtD
Lithium—Hyperglycaemia—Arformoterol—chronic obstructive pulmonary disease	0.0016	0.0038	CcSEcCtD
Lithium—Arrhythmia—Tiotropium—chronic obstructive pulmonary disease	0.00158	0.00373	CcSEcCtD
Lithium—Abdominal pain—Roflumilast—chronic obstructive pulmonary disease	0.00158	0.00373	CcSEcCtD
Lithium—Drowsiness—Montelukast—chronic obstructive pulmonary disease	0.00155	0.00368	CcSEcCtD
Lithium—Tremor—Aminophylline—chronic obstructive pulmonary disease	0.00153	0.00362	CcSEcCtD
Lithium—Hyperglycaemia—Salbutamol—chronic obstructive pulmonary disease	0.00152	0.00359	CcSEcCtD
Lithium—Drowsiness—Salbutamol—chronic obstructive pulmonary disease	0.0015	0.00355	CcSEcCtD
Lithium—Agitation—Aminophylline—chronic obstructive pulmonary disease	0.0015	0.00355	CcSEcCtD
Lithium—Vision blurred—Tiotropium—chronic obstructive pulmonary disease	0.00145	0.00343	CcSEcCtD
Lithium—Asthenia—Roflumilast—chronic obstructive pulmonary disease	0.00143	0.00339	CcSEcCtD
Lithium—Memory impairment—Prednisone—chronic obstructive pulmonary disease	0.00142	0.00337	CcSEcCtD
Lithium—Convulsion—Aminophylline—chronic obstructive pulmonary disease	0.00141	0.00334	CcSEcCtD
Lithium—Angioedema—Tiotropium—chronic obstructive pulmonary disease	0.0014	0.00333	CcSEcCtD
Lithium—Hallucination—Montelukast—chronic obstructive pulmonary disease	0.00139	0.00329	CcSEcCtD
Lithium—Glycosuria—Prednisone—chronic obstructive pulmonary disease	0.00138	0.00326	CcSEcCtD
Lithium—Syncope—Tiotropium—chronic obstructive pulmonary disease	0.00138	0.00326	CcSEcCtD
Lithium—Diarrhoea—Roflumilast—chronic obstructive pulmonary disease	0.00136	0.00323	CcSEcCtD
Lithium—Loss of consciousness—Tiotropium—chronic obstructive pulmonary disease	0.00135	0.0032	CcSEcCtD
Lithium—Dizziness—Roflumilast—chronic obstructive pulmonary disease	0.00132	0.00312	CcSEcCtD
Lithium—Shock—Aminophylline—chronic obstructive pulmonary disease	0.00131	0.0031	CcSEcCtD
Lithium—Arthralgia—Tiotropium—chronic obstructive pulmonary disease	0.00131	0.0031	CcSEcCtD
Lithium—Dry mouth—Tiotropium—chronic obstructive pulmonary disease	0.00128	0.00303	CcSEcCtD
Lithium—Arrhythmia—Arformoterol—chronic obstructive pulmonary disease	0.00127	0.00301	CcSEcCtD
Lithium—Arrhythmia—Formoterol—chronic obstructive pulmonary disease	0.00127	0.00301	CcSEcCtD
Lithium—Vomiting—Roflumilast—chronic obstructive pulmonary disease	0.00127	0.003	CcSEcCtD
Lithium—Anorexia—Aminophylline—chronic obstructive pulmonary disease	0.00127	0.003	CcSEcCtD
Lithium—Rash—Roflumilast—chronic obstructive pulmonary disease	0.00126	0.00298	CcSEcCtD
Lithium—Dermatitis—Roflumilast—chronic obstructive pulmonary disease	0.00126	0.00298	CcSEcCtD
Lithium—Tinnitus—Salbutamol—chronic obstructive pulmonary disease	0.00125	0.00297	CcSEcCtD
Lithium—Oedema—Tiotropium—chronic obstructive pulmonary disease	0.00125	0.00297	CcSEcCtD
Lithium—Headache—Roflumilast—chronic obstructive pulmonary disease	0.00125	0.00296	CcSEcCtD
Lithium—Hypotension—Aminophylline—chronic obstructive pulmonary disease	0.00124	0.00294	CcSEcCtD
Lithium—Shock—Tiotropium—chronic obstructive pulmonary disease	0.00123	0.00292	CcSEcCtD
Lithium—Dysgeusia—Arformoterol—chronic obstructive pulmonary disease	0.00121	0.00288	CcSEcCtD
Lithium—Dysgeusia—Formoterol—chronic obstructive pulmonary disease	0.00121	0.00288	CcSEcCtD
Lithium—Arrhythmia—Salbutamol—chronic obstructive pulmonary disease	0.0012	0.00285	CcSEcCtD
Lithium—Leukocytosis—Prednisone—chronic obstructive pulmonary disease	0.00119	0.00281	CcSEcCtD
Lithium—Nausea—Roflumilast—chronic obstructive pulmonary disease	0.00118	0.00281	CcSEcCtD
Lithium—Dyspepsia—Aminophylline—chronic obstructive pulmonary disease	0.00117	0.00277	CcSEcCtD
Lithium—Tremor—Formoterol—chronic obstructive pulmonary disease	0.00116	0.00275	CcSEcCtD
Lithium—Tremor—Arformoterol—chronic obstructive pulmonary disease	0.00116	0.00275	CcSEcCtD
Lithium—Decreased appetite—Aminophylline—chronic obstructive pulmonary disease	0.00116	0.00274	CcSEcCtD
Lithium—Flatulence—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00273	CcSEcCtD
Lithium—Dysgeusia—Salbutamol—chronic obstructive pulmonary disease	0.00115	0.00272	CcSEcCtD
Lithium—Musculoskeletal discomfort—Tiotropium—chronic obstructive pulmonary disease	0.00114	0.00271	CcSEcCtD
Lithium—Agitation—Formoterol—chronic obstructive pulmonary disease	0.00114	0.0027	CcSEcCtD
Lithium—Agitation—Arformoterol—chronic obstructive pulmonary disease	0.00114	0.0027	CcSEcCtD
Lithium—Tremor—Montelukast—chronic obstructive pulmonary disease	0.00114	0.0027	CcSEcCtD
Lithium—Angioedema—Formoterol—chronic obstructive pulmonary disease	0.00113	0.00268	CcSEcCtD
Lithium—Angioedema—Arformoterol—chronic obstructive pulmonary disease	0.00113	0.00268	CcSEcCtD
Lithium—Agitation—Montelukast—chronic obstructive pulmonary disease	0.00112	0.00264	CcSEcCtD
Lithium—Angioedema—Montelukast—chronic obstructive pulmonary disease	0.00111	0.00263	CcSEcCtD
Lithium—Dyspepsia—Tiotropium—chronic obstructive pulmonary disease	0.0011	0.00261	CcSEcCtD
Lithium—Tremor—Salbutamol—chronic obstructive pulmonary disease	0.0011	0.0026	CcSEcCtD
Lithium—Gastrointestinal pain—Aminophylline—chronic obstructive pulmonary disease	0.00109	0.00258	CcSEcCtD
Lithium—Agitation—Salbutamol—chronic obstructive pulmonary disease	0.00108	0.00255	CcSEcCtD
Lithium—Angioedema—Salbutamol—chronic obstructive pulmonary disease	0.00107	0.00253	CcSEcCtD
Lithium—Arthralgia—Arformoterol—chronic obstructive pulmonary disease	0.00106	0.0025	CcSEcCtD
Lithium—Arthralgia—Formoterol—chronic obstructive pulmonary disease	0.00106	0.0025	CcSEcCtD
Lithium—Convulsion—Montelukast—chronic obstructive pulmonary disease	0.00105	0.00249	CcSEcCtD
Lithium—Vertigo—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00249	CcSEcCtD
Lithium—Body temperature increased—Aminophylline—chronic obstructive pulmonary disease	0.00105	0.00249	CcSEcCtD
Lithium—Abdominal pain—Aminophylline—chronic obstructive pulmonary disease	0.00105	0.00249	CcSEcCtD
Lithium—Syncope—Salbutamol—chronic obstructive pulmonary disease	0.00105	0.00249	CcSEcCtD
Lithium—Discomfort—Arformoterol—chronic obstructive pulmonary disease	0.00104	0.00247	CcSEcCtD
Lithium—Discomfort—Formoterol—chronic obstructive pulmonary disease	0.00104	0.00247	CcSEcCtD
Lithium—Arthralgia—Montelukast—chronic obstructive pulmonary disease	0.00103	0.00245	CcSEcCtD
Lithium—Dry mouth—Arformoterol—chronic obstructive pulmonary disease	0.00103	0.00245	CcSEcCtD
Lithium—Dry mouth—Formoterol—chronic obstructive pulmonary disease	0.00103	0.00245	CcSEcCtD
Lithium—Loss of consciousness—Salbutamol—chronic obstructive pulmonary disease	0.00103	0.00244	CcSEcCtD
Lithium—Gastrointestinal pain—Tiotropium—chronic obstructive pulmonary disease	0.00103	0.00243	CcSEcCtD
Lithium—Dry skin—Prednisolone—chronic obstructive pulmonary disease	0.00102	0.00242	CcSEcCtD
Lithium—Oedema—Arformoterol—chronic obstructive pulmonary disease	0.00101	0.0024	CcSEcCtD
Lithium—Oedema—Formoterol—chronic obstructive pulmonary disease	0.00101	0.0024	CcSEcCtD
Lithium—Arthralgia—Salbutamol—chronic obstructive pulmonary disease	0.000997	0.00236	CcSEcCtD
Lithium—Abdominal pain—Tiotropium—chronic obstructive pulmonary disease	0.000991	0.00235	CcSEcCtD
Lithium—Oedema—Montelukast—chronic obstructive pulmonary disease	0.000991	0.00235	CcSEcCtD
Lithium—Discomfort—Salbutamol—chronic obstructive pulmonary disease	0.000985	0.00233	CcSEcCtD
Lithium—Muscular weakness—Prednisolone—chronic obstructive pulmonary disease	0.000983	0.00233	CcSEcCtD
Lithium—Dry mouth—Salbutamol—chronic obstructive pulmonary disease	0.000975	0.00231	CcSEcCtD
Lithium—Oedema—Salbutamol—chronic obstructive pulmonary disease	0.000955	0.00226	CcSEcCtD
Lithium—Hypotension—Formoterol—chronic obstructive pulmonary disease	0.000945	0.00224	CcSEcCtD
Lithium—Hypotension—Arformoterol—chronic obstructive pulmonary disease	0.000945	0.00224	CcSEcCtD
Lithium—Shock—Salbutamol—chronic obstructive pulmonary disease	0.00094	0.00223	CcSEcCtD
Lithium—Musculoskeletal discomfort—Arformoterol—chronic obstructive pulmonary disease	0.000922	0.00218	CcSEcCtD
Lithium—Musculoskeletal discomfort—Formoterol—chronic obstructive pulmonary disease	0.000922	0.00218	CcSEcCtD
Lithium—Anorexia—Salbutamol—chronic obstructive pulmonary disease	0.000911	0.00216	CcSEcCtD
Lithium—Diarrhoea—Aminophylline—chronic obstructive pulmonary disease	0.00091	0.00216	CcSEcCtD
Lithium—Musculoskeletal discomfort—Montelukast—chronic obstructive pulmonary disease	0.000903	0.00214	CcSEcCtD
Lithium—Somnolence—Formoterol—chronic obstructive pulmonary disease	0.000899	0.00213	CcSEcCtD
Lithium—Somnolence—Arformoterol—chronic obstructive pulmonary disease	0.000899	0.00213	CcSEcCtD
Lithium—Hypotension—Salbutamol—chronic obstructive pulmonary disease	0.000893	0.00212	CcSEcCtD
Lithium—Dyspepsia—Arformoterol—chronic obstructive pulmonary disease	0.000891	0.00211	CcSEcCtD
Lithium—Dyspepsia—Formoterol—chronic obstructive pulmonary disease	0.000891	0.00211	CcSEcCtD
Lithium—Somnolence—Montelukast—chronic obstructive pulmonary disease	0.000881	0.00209	CcSEcCtD
Lithium—Dizziness—Aminophylline—chronic obstructive pulmonary disease	0.000879	0.00208	CcSEcCtD
Lithium—Weight increased—Prednisolone—chronic obstructive pulmonary disease	0.000877	0.00208	CcSEcCtD
Lithium—Dyspepsia—Montelukast—chronic obstructive pulmonary disease	0.000872	0.00207	CcSEcCtD
Lithium—Fatigue—Formoterol—chronic obstructive pulmonary disease	0.000872	0.00207	CcSEcCtD
Lithium—Fatigue—Arformoterol—chronic obstructive pulmonary disease	0.000872	0.00207	CcSEcCtD
Lithium—Musculoskeletal discomfort—Salbutamol—chronic obstructive pulmonary disease	0.00087	0.00206	CcSEcCtD
Lithium—Fatigue—Montelukast—chronic obstructive pulmonary disease	0.000854	0.00202	CcSEcCtD
Lithium—Somnolence—Salbutamol—chronic obstructive pulmonary disease	0.000849	0.00201	CcSEcCtD
Lithium—Vomiting—Aminophylline—chronic obstructive pulmonary disease	0.000845	0.002	CcSEcCtD
Lithium—Dyspepsia—Salbutamol—chronic obstructive pulmonary disease	0.000841	0.00199	CcSEcCtD
Lithium—Rash—Aminophylline—chronic obstructive pulmonary disease	0.000838	0.00199	CcSEcCtD
Lithium—Dermatitis—Aminophylline—chronic obstructive pulmonary disease	0.000837	0.00198	CcSEcCtD
Lithium—Feeling abnormal—Arformoterol—chronic obstructive pulmonary disease	0.000834	0.00198	CcSEcCtD
Lithium—Feeling abnormal—Formoterol—chronic obstructive pulmonary disease	0.000834	0.00198	CcSEcCtD
Lithium—Headache—Aminophylline—chronic obstructive pulmonary disease	0.000833	0.00197	CcSEcCtD
Lithium—Decreased appetite—Salbutamol—chronic obstructive pulmonary disease	0.00083	0.00197	CcSEcCtD
Lithium—Dizziness—Tiotropium—chronic obstructive pulmonary disease	0.000829	0.00196	CcSEcCtD
Lithium—Gastrointestinal pain—Formoterol—chronic obstructive pulmonary disease	0.000827	0.00196	CcSEcCtD
Lithium—Gastrointestinal pain—Arformoterol—chronic obstructive pulmonary disease	0.000827	0.00196	CcSEcCtD
Lithium—Lethargy—Prednisone—chronic obstructive pulmonary disease	0.000827	0.00196	CcSEcCtD
Lithium—Fatigue—Salbutamol—chronic obstructive pulmonary disease	0.000824	0.00195	CcSEcCtD
Lithium—Gastrointestinal pain—Montelukast—chronic obstructive pulmonary disease	0.00081	0.00192	CcSEcCtD
Lithium—Abdominal pain—Arformoterol—chronic obstructive pulmonary disease	0.0008	0.00189	CcSEcCtD
Lithium—Body temperature increased—Arformoterol—chronic obstructive pulmonary disease	0.0008	0.00189	CcSEcCtD
Lithium—Abdominal pain—Formoterol—chronic obstructive pulmonary disease	0.0008	0.00189	CcSEcCtD
Lithium—Body temperature increased—Formoterol—chronic obstructive pulmonary disease	0.0008	0.00189	CcSEcCtD
Lithium—Vomiting—Tiotropium—chronic obstructive pulmonary disease	0.000797	0.00189	CcSEcCtD
Lithium—Rash—Tiotropium—chronic obstructive pulmonary disease	0.00079	0.00187	CcSEcCtD
Lithium—Dermatitis—Tiotropium—chronic obstructive pulmonary disease	0.00079	0.00187	CcSEcCtD
Lithium—Nausea—Aminophylline—chronic obstructive pulmonary disease	0.00079	0.00187	CcSEcCtD
Lithium—Feeling abnormal—Salbutamol—chronic obstructive pulmonary disease	0.000787	0.00187	CcSEcCtD
Lithium—Headache—Tiotropium—chronic obstructive pulmonary disease	0.000785	0.00186	CcSEcCtD
Lithium—Bradycardia—Prednisolone—chronic obstructive pulmonary disease	0.000785	0.00186	CcSEcCtD
Lithium—Body temperature increased—Montelukast—chronic obstructive pulmonary disease	0.000783	0.00186	CcSEcCtD
Lithium—Abdominal pain—Montelukast—chronic obstructive pulmonary disease	0.000783	0.00186	CcSEcCtD
Lithium—Gastrointestinal pain—Salbutamol—chronic obstructive pulmonary disease	0.000781	0.00185	CcSEcCtD
Lithium—GSK3A—Immune System—LY96—chronic obstructive pulmonary disease	0.00077	0.00208	CbGpPWpGaD
Lithium—GSK3A—PI-3K cascade—EGFR—chronic obstructive pulmonary disease	0.00076	0.00205	CbGpPWpGaD
Lithium—GSK3B—ErbB Signaling Pathway—TP53—chronic obstructive pulmonary disease	0.000759	0.00205	CbGpPWpGaD
Lithium—Abdominal pain—Salbutamol—chronic obstructive pulmonary disease	0.000755	0.00179	CcSEcCtD
Lithium—Body temperature increased—Salbutamol—chronic obstructive pulmonary disease	0.000755	0.00179	CcSEcCtD
Lithium—GSK3B—B Cell Activation—ERBB3—chronic obstructive pulmonary disease	0.000745	0.00201	CbGpPWpGaD
Lithium—Nausea—Tiotropium—chronic obstructive pulmonary disease	0.000745	0.00176	CcSEcCtD
Lithium—Dry skin—Prednisone—chronic obstructive pulmonary disease	0.000743	0.00176	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—ERBB3—chronic obstructive pulmonary disease	0.000742	0.002	CbGpPWpGaD
Lithium—GSK3A—PI3K/AKT activation—EGFR—chronic obstructive pulmonary disease	0.000741	0.002	CbGpPWpGaD
Lithium—GSK3A—GAB1 signalosome—EGFR—chronic obstructive pulmonary disease	0.000736	0.00199	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—KL—chronic obstructive pulmonary disease	0.000731	0.00197	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—CXCL8—chronic obstructive pulmonary disease	0.000727	0.00196	CbGpPWpGaD
Lithium—Asthenia—Formoterol—chronic obstructive pulmonary disease	0.000726	0.00172	CcSEcCtD
Lithium—Asthenia—Arformoterol—chronic obstructive pulmonary disease	0.000726	0.00172	CcSEcCtD
Lithium—GSK3A—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—chronic obstructive pulmonary disease	0.000719	0.00194	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CYP1A2—chronic obstructive pulmonary disease	0.000718	0.00194	CbGpPWpGaD
Lithium—Muscular weakness—Prednisone—chronic obstructive pulmonary disease	0.000715	0.00169	CcSEcCtD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—ERBB3—chronic obstructive pulmonary disease	0.000713	0.00192	CbGpPWpGaD
Lithium—Asthenia—Montelukast—chronic obstructive pulmonary disease	0.000711	0.00168	CcSEcCtD
Lithium—GSK3B—p53 pathway—TP53—chronic obstructive pulmonary disease	0.000707	0.00191	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—MMP9—chronic obstructive pulmonary disease	0.000703	0.0019	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL1B—chronic obstructive pulmonary disease	0.000697	0.00188	CbGpPWpGaD
Lithium—Diarrhoea—Arformoterol—chronic obstructive pulmonary disease	0.000692	0.00164	CcSEcCtD
Lithium—Diarrhoea—Formoterol—chronic obstructive pulmonary disease	0.000692	0.00164	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—GSTP1—chronic obstructive pulmonary disease	0.000692	0.00187	CbGpPWpGaD
Lithium—Arrhythmia—Prednisolone—chronic obstructive pulmonary disease	0.000689	0.00163	CcSEcCtD
Lithium—Asthenia—Salbutamol—chronic obstructive pulmonary disease	0.000685	0.00162	CcSEcCtD
Lithium—Diarrhoea—Montelukast—chronic obstructive pulmonary disease	0.000678	0.00161	CcSEcCtD
Lithium—IMPA2—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000672	0.00181	CbGpPWpGaD
Lithium—Dizziness—Arformoterol—chronic obstructive pulmonary disease	0.000669	0.00159	CcSEcCtD
Lithium—Dizziness—Formoterol—chronic obstructive pulmonary disease	0.000669	0.00159	CcSEcCtD
Lithium—IMPA2—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000663	0.00179	CbGpPWpGaD
Lithium—Dizziness—Montelukast—chronic obstructive pulmonary disease	0.000655	0.00155	CcSEcCtD
Lithium—Diarrhoea—Salbutamol—chronic obstructive pulmonary disease	0.000654	0.00155	CcSEcCtD
Lithium—GSK3B—Circadian rythm related genes—LEP—chronic obstructive pulmonary disease	0.00065	0.00176	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TGFB1—chronic obstructive pulmonary disease	0.000648	0.00175	CbGpPWpGaD
Lithium—Erectile dysfunction—Prednisone—chronic obstructive pulmonary disease	0.000645	0.00153	CcSEcCtD
Lithium—Vomiting—Formoterol—chronic obstructive pulmonary disease	0.000643	0.00152	CcSEcCtD
Lithium—Vomiting—Arformoterol—chronic obstructive pulmonary disease	0.000643	0.00152	CcSEcCtD
Lithium—Rash—Arformoterol—chronic obstructive pulmonary disease	0.000638	0.00151	CcSEcCtD
Lithium—Rash—Formoterol—chronic obstructive pulmonary disease	0.000638	0.00151	CcSEcCtD
Lithium—Dermatitis—Formoterol—chronic obstructive pulmonary disease	0.000637	0.00151	CcSEcCtD
Lithium—Dermatitis—Arformoterol—chronic obstructive pulmonary disease	0.000637	0.00151	CcSEcCtD
Lithium—Weight increased—Prednisone—chronic obstructive pulmonary disease	0.000637	0.00151	CcSEcCtD
Lithium—GSK3B—Alzheimers Disease—TNF—chronic obstructive pulmonary disease	0.000635	0.00171	CbGpPWpGaD
Lithium—Headache—Arformoterol—chronic obstructive pulmonary disease	0.000634	0.0015	CcSEcCtD
Lithium—Headache—Formoterol—chronic obstructive pulmonary disease	0.000634	0.0015	CcSEcCtD
Lithium—Weight decreased—Prednisone—chronic obstructive pulmonary disease	0.000633	0.0015	CcSEcCtD
Lithium—Vision blurred—Prednisolone—chronic obstructive pulmonary disease	0.000633	0.0015	CcSEcCtD
Lithium—Dizziness—Salbutamol—chronic obstructive pulmonary disease	0.000632	0.0015	CcSEcCtD
Lithium—Hyperglycaemia—Prednisone—chronic obstructive pulmonary disease	0.000632	0.0015	CcSEcCtD
Lithium—Vomiting—Montelukast—chronic obstructive pulmonary disease	0.00063	0.00149	CcSEcCtD
Lithium—Rash—Montelukast—chronic obstructive pulmonary disease	0.000625	0.00148	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—FAM13A—chronic obstructive pulmonary disease	0.000624	0.00169	CbGpPWpGaD
Lithium—Dermatitis—Montelukast—chronic obstructive pulmonary disease	0.000624	0.00148	CcSEcCtD
Lithium—GSK3B—Constitutive PI3K/AKT Signaling in Cancer—EGFR—chronic obstructive pulmonary disease	0.000623	0.00168	CbGpPWpGaD
Lithium—Headache—Montelukast—chronic obstructive pulmonary disease	0.000621	0.00147	CcSEcCtD
Lithium—IMPA2—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000618	0.00167	CbGpPWpGaD
Lithium—Angioedema—Prednisolone—chronic obstructive pulmonary disease	0.000613	0.00145	CcSEcCtD
Lithium—Vomiting—Salbutamol—chronic obstructive pulmonary disease	0.000607	0.00144	CcSEcCtD
Lithium—GSK3B—Androgen receptor signaling pathway—EGFR—chronic obstructive pulmonary disease	0.000606	0.00164	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—NOS2—chronic obstructive pulmonary disease	0.000606	0.00164	CbGpPWpGaD
Lithium—GSK3B—MicroRNAs in cardiomyocyte hypertrophy—TNF—chronic obstructive pulmonary disease	0.000605	0.00163	CbGpPWpGaD
Lithium—Vertigo—Prednisolone—chronic obstructive pulmonary disease	0.000603	0.00143	CcSEcCtD
Lithium—Rash—Salbutamol—chronic obstructive pulmonary disease	0.000602	0.00143	CcSEcCtD
Lithium—GSK3B—Corticotropin-releasing hormone—TGFB1—chronic obstructive pulmonary disease	0.000602	0.00163	CbGpPWpGaD
Lithium—Syncope—Prednisolone—chronic obstructive pulmonary disease	0.000602	0.00143	CcSEcCtD
Lithium—Dermatitis—Salbutamol—chronic obstructive pulmonary disease	0.000602	0.00143	CcSEcCtD
Lithium—Nausea—Arformoterol—chronic obstructive pulmonary disease	0.000601	0.00142	CcSEcCtD
Lithium—Nausea—Formoterol—chronic obstructive pulmonary disease	0.000601	0.00142	CcSEcCtD
Lithium—GSK3A—Innate Immune System—TLR2—chronic obstructive pulmonary disease	0.0006	0.00162	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GSTP1—chronic obstructive pulmonary disease	0.000599	0.00162	CbGpPWpGaD
Lithium—Headache—Salbutamol—chronic obstructive pulmonary disease	0.000598	0.00142	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000597	0.00161	CbGpPWpGaD
Lithium—IMPA1—Metabolism—HMOX1—chronic obstructive pulmonary disease	0.000591	0.0016	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisolone—chronic obstructive pulmonary disease	0.00059	0.0014	CcSEcCtD
Lithium—Nausea—Montelukast—chronic obstructive pulmonary disease	0.000589	0.00139	CcSEcCtD
Lithium—IMPA2—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000586	0.00158	CbGpPWpGaD
Lithium—GSK3B—Immune System—RAPGEF3—chronic obstructive pulmonary disease	0.000585	0.00158	CbGpPWpGaD
Lithium—Convulsion—Prednisolone—chronic obstructive pulmonary disease	0.000582	0.00138	CcSEcCtD
Lithium—Bradycardia—Prednisone—chronic obstructive pulmonary disease	0.000571	0.00135	CcSEcCtD
Lithium—GSK3B—Immune System—LY96—chronic obstructive pulmonary disease	0.000569	0.00154	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—EGFR—chronic obstructive pulmonary disease	0.000568	0.00153	CbGpPWpGaD
Lithium—Nausea—Salbutamol—chronic obstructive pulmonary disease	0.000567	0.00134	CcSEcCtD
Lithium—Discomfort—Prednisolone—chronic obstructive pulmonary disease	0.000565	0.00134	CcSEcCtD
Lithium—GSK3A—Innate Immune System—KL—chronic obstructive pulmonary disease	0.000565	0.00152	CbGpPWpGaD
Lithium—GSK3B—PI-3K cascade—EGFR—chronic obstructive pulmonary disease	0.000561	0.00152	CbGpPWpGaD
Lithium—GSK3B—Alzheimers Disease—TP53—chronic obstructive pulmonary disease	0.00056	0.00151	CbGpPWpGaD
Lithium—Hallucination—Prednisone—chronic obstructive pulmonary disease	0.000558	0.00132	CcSEcCtD
Lithium—GSK3B—Cell Cycle—TGFB1—chronic obstructive pulmonary disease	0.000554	0.0015	CbGpPWpGaD
Lithium—IMPA1—Metabolism—GSTM1—chronic obstructive pulmonary disease	0.000551	0.00149	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—ERBB3—chronic obstructive pulmonary disease	0.000548	0.00148	CbGpPWpGaD
Lithium—Oedema—Prednisolone—chronic obstructive pulmonary disease	0.000548	0.0013	CcSEcCtD
Lithium—GSK3B—PI3K/AKT activation—EGFR—chronic obstructive pulmonary disease	0.000548	0.00148	CbGpPWpGaD
Lithium—GSK3B—GAB1 signalosome—EGFR—chronic obstructive pulmonary disease	0.000544	0.00147	CbGpPWpGaD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—TP53—chronic obstructive pulmonary disease	0.000543	0.00147	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—EGFR—chronic obstructive pulmonary disease	0.000543	0.00147	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—KL—chronic obstructive pulmonary disease	0.000542	0.00146	CbGpPWpGaD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TGFB1—chronic obstructive pulmonary disease	0.000542	0.00146	CbGpPWpGaD
Lithium—Shock—Prednisolone—chronic obstructive pulmonary disease	0.000539	0.00128	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000537	0.00145	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB4—EGFR—chronic obstructive pulmonary disease	0.000535	0.00144	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—ACE—chronic obstructive pulmonary disease	0.000533	0.00144	CbGpPWpGaD
Lithium—GSK3B—Role of LAT2/NTAL/LAB on calcium mobilization—EGFR—chronic obstructive pulmonary disease	0.000531	0.00143	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TGFB1—chronic obstructive pulmonary disease	0.000526	0.00142	CbGpPWpGaD
Lithium—IMPA1—Metabolism—CYP1A1—chronic obstructive pulmonary disease	0.000522	0.00141	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—MMP9—chronic obstructive pulmonary disease	0.000519	0.0014	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000512	0.00138	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—EGFR—chronic obstructive pulmonary disease	0.000511	0.00138	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—SERPINE1—chronic obstructive pulmonary disease	0.00051	0.00138	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—ADIPOQ—chronic obstructive pulmonary disease	0.00051	0.00138	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR—EGFR—chronic obstructive pulmonary disease	0.000508	0.00137	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—EGFR—chronic obstructive pulmonary disease	0.000506	0.00137	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—EGFR—chronic obstructive pulmonary disease	0.000503	0.00136	CbGpPWpGaD
Lithium—Arrhythmia—Prednisone—chronic obstructive pulmonary disease	0.000501	0.00119	CcSEcCtD
Lithium—GSK3B—Glucocorticoid receptor regulatory network—IL6—chronic obstructive pulmonary disease	0.000497	0.00134	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling events of B Cell Receptor (BCR)—EGFR—chronic obstructive pulmonary disease	0.000496	0.00134	CbGpPWpGaD
Lithium—Alopecia—Prednisone—chronic obstructive pulmonary disease	0.000495	0.00117	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—VEGFA—chronic obstructive pulmonary disease	0.000495	0.00134	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—PLAUR—chronic obstructive pulmonary disease	0.000478	0.00129	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	0.000473	0.00128	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	0.000473	0.00128	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	0.000473	0.00128	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	0.000469	0.00127	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	0.000465	0.00126	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	0.000463	0.00125	CbGpPWpGaD
Lithium—Vision blurred—Prednisone—chronic obstructive pulmonary disease	0.00046	0.00109	CcSEcCtD
Lithium—GSK3B—Cell Cycle—TP53—chronic obstructive pulmonary disease	0.000456	0.00123	CbGpPWpGaD
Lithium—GSK3B—Wnt Signaling Pathway and Pluripotency—TP53—chronic obstructive pulmonary disease	0.000456	0.00123	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TGFB1—chronic obstructive pulmonary disease	0.000454	0.00123	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisolone—chronic obstructive pulmonary disease	0.000452	0.00107	CcSEcCtD
Lithium—GSK3A—Integrated Breast Cancer Pathway—TP53—chronic obstructive pulmonary disease	0.000451	0.00122	CbGpPWpGaD
Lithium—Agitation—Prednisone—chronic obstructive pulmonary disease	0.000448	0.00106	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—TP53—chronic obstructive pulmonary disease	0.000446	0.0012	CbGpPWpGaD
Lithium—Angioedema—Prednisone—chronic obstructive pulmonary disease	0.000446	0.00106	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—EGFR—chronic obstructive pulmonary disease	0.000445	0.0012	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR2—chronic obstructive pulmonary disease	0.000444	0.0012	CbGpPWpGaD
Lithium—Vertigo—Prednisone—chronic obstructive pulmonary disease	0.000438	0.00104	CcSEcCtD
Lithium—GSK3A—B Cell Activation—EGFR—chronic obstructive pulmonary disease	0.000438	0.00118	CbGpPWpGaD
Lithium—Syncope—Prednisone—chronic obstructive pulmonary disease	0.000438	0.00104	CcSEcCtD
Lithium—GSK3A—Adaptive Immune System—CD8A—chronic obstructive pulmonary disease	0.000437	0.00118	CbGpPWpGaD
Lithium—GSK3A—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	0.000436	0.00118	CbGpPWpGaD
Lithium—GSK3B—DNA Damage Response (only ATM dependent)—TP53—chronic obstructive pulmonary disease	0.000433	0.00117	CbGpPWpGaD
Lithium—Loss of consciousness—Prednisone—chronic obstructive pulmonary disease	0.000429	0.00102	CcSEcCtD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TNF—chronic obstructive pulmonary disease	0.000424	0.00115	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	0.000423	0.00114	CbGpPWpGaD
Lithium—Convulsion—Prednisone—chronic obstructive pulmonary disease	0.000423	0.001	CcSEcCtD
Lithium—GSK3B—Signaling by SCF-KIT—EGFR—chronic obstructive pulmonary disease	0.00042	0.00113	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	0.000419	0.00113	CbGpPWpGaD
Lithium—GSK3A—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	0.000418	0.00113	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—KL—chronic obstructive pulmonary disease	0.000417	0.00113	CbGpPWpGaD
Lithium—Arthralgia—Prednisone—chronic obstructive pulmonary disease	0.000415	0.000984	CcSEcCtD
Lithium—GSK3A—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	0.000411	0.00111	CbGpPWpGaD
Lithium—Discomfort—Prednisone—chronic obstructive pulmonary disease	0.00041	0.000972	CcSEcCtD
Lithium—GSK3B—Senescence and Autophagy in Cancer—IL6—chronic obstructive pulmonary disease	0.000408	0.0011	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—ERBB3—chronic obstructive pulmonary disease	0.000406	0.0011	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—EGFR—chronic obstructive pulmonary disease	0.000401	0.00108	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—KL—chronic obstructive pulmonary disease	0.000401	0.00108	CbGpPWpGaD
Lithium—Oedema—Prednisone—chronic obstructive pulmonary disease	0.000398	0.000943	CcSEcCtD
Lithium—IMPA2—Metabolism—ALB—chronic obstructive pulmonary disease	0.000398	0.00107	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—EGFR—chronic obstructive pulmonary disease	0.000395	0.00107	CbGpPWpGaD
Lithium—GSK3A—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	0.000392	0.00106	CbGpPWpGaD
Lithium—Shock—Prednisone—chronic obstructive pulmonary disease	0.000392	0.000928	CcSEcCtD
Lithium—GSK3A—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	0.00039	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	0.000389	0.00105	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000388	0.00105	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—CRP—chronic obstructive pulmonary disease	0.000387	0.00104	CbGpPWpGaD
Lithium—GSK3A—DAP12 signaling—IL6—chronic obstructive pulmonary disease	0.000387	0.00104	CbGpPWpGaD
Lithium—IMPA2—Metabolism—NOS3—chronic obstructive pulmonary disease	0.000381	0.00103	CbGpPWpGaD
Lithium—Anorexia—Prednisone—chronic obstructive pulmonary disease	0.00038	0.000899	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—RAPGEF3—chronic obstructive pulmonary disease	0.000378	0.00102	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—EGFR—chronic obstructive pulmonary disease	0.000377	0.00102	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—EGFR—chronic obstructive pulmonary disease	0.000375	0.00101	CbGpPWpGaD
Lithium—GSK3A—Integrated Pancreatic Cancer Pathway—TP53—chronic obstructive pulmonary disease	0.000374	0.00101	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—EGFR—chronic obstructive pulmonary disease	0.000374	0.00101	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—EGFR—chronic obstructive pulmonary disease	0.000372	0.001	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—TLR4—chronic obstructive pulmonary disease	0.000371	0.001	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—VEGFA—chronic obstructive pulmonary disease	0.000367	0.000992	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling events of B Cell Receptor (BCR)—EGFR—chronic obstructive pulmonary disease	0.000366	0.000989	CbGpPWpGaD
Lithium—GSK3A—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	0.000364	0.000982	CbGpPWpGaD
Lithium—GSK3A—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	0.000364	0.000982	CbGpPWpGaD
Lithium—GSK3A—DAP12 interactions—IL6—chronic obstructive pulmonary disease	0.000364	0.000982	CbGpPWpGaD
Lithium—Musculoskeletal discomfort—Prednisone—chronic obstructive pulmonary disease	0.000363	0.000859	CcSEcCtD
Lithium—Dizziness—Prednisolone—chronic obstructive pulmonary disease	0.000362	0.000858	CcSEcCtD
Lithium—GSK3A—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	0.000361	0.000973	CbGpPWpGaD
Lithium—GSK3A—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	0.000357	0.000965	CbGpPWpGaD
Lithium—GSK3A—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	0.000356	0.000961	CbGpPWpGaD
Lithium—IMPA1—Metabolism—ALB—chronic obstructive pulmonary disease	0.000355	0.000958	CbGpPWpGaD
Lithium—Dyspepsia—Prednisone—chronic obstructive pulmonary disease	0.000351	0.00083	CcSEcCtD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—EGFR—chronic obstructive pulmonary disease	0.00035	0.000944	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—EGFR—chronic obstructive pulmonary disease	0.00035	0.000944	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—EGFR—chronic obstructive pulmonary disease	0.00035	0.000944	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR2—chronic obstructive pulmonary disease	0.00035	0.000944	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—CXCL8—chronic obstructive pulmonary disease	0.000348	0.000938	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—EGFR—chronic obstructive pulmonary disease	0.000347	0.000936	CbGpPWpGaD
Lithium—Decreased appetite—Prednisone—chronic obstructive pulmonary disease	0.000346	0.00082	CcSEcCtD
Lithium—Rash—Prednisolone—chronic obstructive pulmonary disease	0.000345	0.000819	CcSEcCtD
Lithium—Dermatitis—Prednisolone—chronic obstructive pulmonary disease	0.000345	0.000818	CcSEcCtD
Lithium—GSK3B—Signaling by EGFR in Cancer—EGFR—chronic obstructive pulmonary disease	0.000344	0.000928	CbGpPWpGaD
Lithium—Fatigue—Prednisone—chronic obstructive pulmonary disease	0.000343	0.000813	CcSEcCtD
Lithium—Headache—Prednisolone—chronic obstructive pulmonary disease	0.000343	0.000813	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—EGFR—chronic obstructive pulmonary disease	0.000342	0.000924	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—MMP1—chronic obstructive pulmonary disease	0.000342	0.000923	CbGpPWpGaD
Lithium—IMPA1—Metabolism—NOS3—chronic obstructive pulmonary disease	0.000339	0.000916	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—LEP—chronic obstructive pulmonary disease	0.000331	0.000893	CbGpPWpGaD
Lithium—GSK3B—Focal Adhesion—EGFR—chronic obstructive pulmonary disease	0.00033	0.000892	CbGpPWpGaD
Lithium—GSK3A—Immune System—KL—chronic obstructive pulmonary disease	0.000329	0.000888	CbGpPWpGaD
Lithium—Feeling abnormal—Prednisone—chronic obstructive pulmonary disease	0.000328	0.000777	CcSEcCtD
Lithium—GSK3A—Disease—HDAC2—chronic obstructive pulmonary disease	0.000327	0.000882	CbGpPWpGaD
Lithium—Gastrointestinal pain—Prednisone—chronic obstructive pulmonary disease	0.000326	0.000771	CcSEcCtD
Lithium—Nausea—Prednisolone—chronic obstructive pulmonary disease	0.000325	0.000771	CcSEcCtD
Lithium—GSK3B—B Cell Activation—EGFR—chronic obstructive pulmonary disease	0.000324	0.000874	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—CD8A—chronic obstructive pulmonary disease	0.000323	0.000872	CbGpPWpGaD
Lithium—GSK3A—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	0.000322	0.000871	CbGpPWpGaD
Lithium—GSK3B—Signaling by SCF-KIT—IL6—chronic obstructive pulmonary disease	0.000322	0.000871	CbGpPWpGaD
Lithium—GSK3A—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	0.000322	0.00087	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—LEP—chronic obstructive pulmonary disease	0.000317	0.000855	CbGpPWpGaD
Lithium—Abdominal pain—Prednisone—chronic obstructive pulmonary disease	0.000315	0.000746	CcSEcCtD
Lithium—Body temperature increased—Prednisone—chronic obstructive pulmonary disease	0.000315	0.000746	CcSEcCtD
Lithium—GSK3A—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000313	0.000844	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—ERBB3—chronic obstructive pulmonary disease	0.000313	0.000844	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—EGFR—chronic obstructive pulmonary disease	0.00031	0.000836	CbGpPWpGaD
Lithium—GSK3B—Downstream signaling of activated FGFR—IL6—chronic obstructive pulmonary disease	0.000309	0.000833	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB4—IL6—chronic obstructive pulmonary disease	0.000304	0.00082	CbGpPWpGaD
Lithium—GSK3A—Disease—KL—chronic obstructive pulmonary disease	0.000304	0.00082	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—ERBB3—chronic obstructive pulmonary disease	0.0003	0.000811	CbGpPWpGaD
Lithium—GSK3B—Downstream signal transduction—IL6—chronic obstructive pulmonary disease	0.00029	0.000783	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR—IL6—chronic obstructive pulmonary disease	0.000289	0.000779	CbGpPWpGaD
Lithium—GSK3B—Signaling by ERBB2—IL6—chronic obstructive pulmonary disease	0.000287	0.000775	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—PDE4A—chronic obstructive pulmonary disease	0.000287	0.000774	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—CRP—chronic obstructive pulmonary disease	0.000286	0.000772	CbGpPWpGaD
Lithium—GSK3B—DAP12 signaling—IL6—chronic obstructive pulmonary disease	0.000286	0.000771	CbGpPWpGaD
Lithium—Asthenia—Prednisone—chronic obstructive pulmonary disease	0.000286	0.000677	CcSEcCtD
Lithium—GSK3B—Cellular responses to stress—VEGFA—chronic obstructive pulmonary disease	0.000282	0.000762	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—TLR4—chronic obstructive pulmonary disease	0.000274	0.00074	CbGpPWpGaD
Lithium—Diarrhoea—Prednisone—chronic obstructive pulmonary disease	0.000272	0.000645	CcSEcCtD
Lithium—GSK3B—Fc epsilon receptor (FCERI) signaling—IL6—chronic obstructive pulmonary disease	0.000269	0.000726	CbGpPWpGaD
Lithium—GSK3B—Signaling by FGFR in disease—IL6—chronic obstructive pulmonary disease	0.000269	0.000726	CbGpPWpGaD
Lithium—GSK3B—DAP12 interactions—IL6—chronic obstructive pulmonary disease	0.000269	0.000726	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—MMP9—chronic obstructive pulmonary disease	0.000267	0.000721	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR—IL6—chronic obstructive pulmonary disease	0.000266	0.000719	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—TP53—chronic obstructive pulmonary disease	0.000265	0.000716	CbGpPWpGaD
Lithium—GSK3A—Immune System—CD8A—chronic obstructive pulmonary disease	0.000265	0.000716	CbGpPWpGaD
Lithium—GSK3B—Signaling by EGFR in Cancer—IL6—chronic obstructive pulmonary disease	0.000264	0.000713	CbGpPWpGaD
Lithium—Dizziness—Prednisone—chronic obstructive pulmonary disease	0.000263	0.000624	CcSEcCtD
Lithium—GSK3B—Signaling by PDGF—IL6—chronic obstructive pulmonary disease	0.000263	0.00071	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR2—chronic obstructive pulmonary disease	0.000258	0.000698	CbGpPWpGaD
Lithium—Vomiting—Prednisone—chronic obstructive pulmonary disease	0.000253	0.0006	CcSEcCtD
Lithium—Rash—Prednisone—chronic obstructive pulmonary disease	0.000251	0.000595	CcSEcCtD
Lithium—Dermatitis—Prednisone—chronic obstructive pulmonary disease	0.000251	0.000594	CcSEcCtD
Lithium—Headache—Prednisone—chronic obstructive pulmonary disease	0.000249	0.000591	CcSEcCtD
Lithium—GSK3A—Signaling by NGF—IL6—chronic obstructive pulmonary disease	0.000248	0.000669	CbGpPWpGaD
Lithium—GSK3A—Immune System—ERBB3—chronic obstructive pulmonary disease	0.000246	0.000665	CbGpPWpGaD
Lithium—GSK3B—Immune System—KL—chronic obstructive pulmonary disease	0.000243	0.000656	CbGpPWpGaD
Lithium—GSK3B—Circadian rythm related genes—IL6—chronic obstructive pulmonary disease	0.000243	0.000656	CbGpPWpGaD
Lithium—GSK3B—Disease—HDAC2—chronic obstructive pulmonary disease	0.000241	0.000652	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—VEGFA—chronic obstructive pulmonary disease	0.00024	0.000647	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—EGFR—chronic obstructive pulmonary disease	0.000238	0.000643	CbGpPWpGaD
Lithium—GSK3B—NGF signalling via TRKA from the plasma membrane—IL6—chronic obstructive pulmonary disease	0.000238	0.000643	CbGpPWpGaD
Lithium—Nausea—Prednisone—chronic obstructive pulmonary disease	0.000237	0.00056	CcSEcCtD
Lithium—GSK3B—Signaling Pathways—CXCR2—chronic obstructive pulmonary disease	0.000231	0.000624	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000229	0.000617	CbGpPWpGaD
Lithium—GSK3A—Disease—ERBB3—chronic obstructive pulmonary disease	0.000228	0.000614	CbGpPWpGaD
Lithium—GSK3A—Immune System—CRP—chronic obstructive pulmonary disease	0.000225	0.000608	CbGpPWpGaD
Lithium—GSK3B—Disease—KL—chronic obstructive pulmonary disease	0.000224	0.000606	CbGpPWpGaD
Lithium—GSK3A—Metabolism of proteins—CXCL8—chronic obstructive pulmonary disease	0.00022	0.000594	CbGpPWpGaD
Lithium—GSK3A—Immune System—TLR4—chronic obstructive pulmonary disease	0.000216	0.000583	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—EGFR—chronic obstructive pulmonary disease	0.000216	0.000582	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—TP53—chronic obstructive pulmonary disease	0.000213	0.000576	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000213	0.000574	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000196	0.00053	CbGpPWpGaD
Lithium—GSK3B—Immune System—CD8A—chronic obstructive pulmonary disease	0.000196	0.000529	CbGpPWpGaD
Lithium—GSK3B—Cellular responses to stress—IL6—chronic obstructive pulmonary disease	0.000195	0.000527	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—MMP9—chronic obstructive pulmonary disease	0.00019	0.000514	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS2—chronic obstructive pulmonary disease	0.00019	0.000512	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—EGFR—chronic obstructive pulmonary disease	0.000184	0.000497	CbGpPWpGaD
Lithium—GSK3B—Signaling by NGF—IL6—chronic obstructive pulmonary disease	0.000183	0.000494	CbGpPWpGaD
Lithium—GSK3B—Immune System—ERBB3—chronic obstructive pulmonary disease	0.000182	0.000492	CbGpPWpGaD
Lithium—GSK3A—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	0.000177	0.000477	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.000175	0.000473	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—VEGFA—chronic obstructive pulmonary disease	0.000171	0.000462	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HDAC2—chronic obstructive pulmonary disease	0.000169	0.000456	CbGpPWpGaD
Lithium—GSK3B—Disease—ERBB3—chronic obstructive pulmonary disease	0.000168	0.000454	CbGpPWpGaD
Lithium—GSK3B—Immune System—CRP—chronic obstructive pulmonary disease	0.000167	0.00045	CbGpPWpGaD
Lithium—GSK3B—Axon guidance—IL6—chronic obstructive pulmonary disease	0.000166	0.000447	CbGpPWpGaD
Lithium—GSK3A—Disease—SERPINE1—chronic obstructive pulmonary disease	0.00016	0.000431	CbGpPWpGaD
Lithium—GSK3B—Immune System—TLR4—chronic obstructive pulmonary disease	0.00016	0.000431	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000159	0.00043	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—KL—chronic obstructive pulmonary disease	0.000157	0.000424	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TGFB1—chronic obstructive pulmonary disease	0.000157	0.000424	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—EGFR—chronic obstructive pulmonary disease	0.000154	0.000415	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000153	0.000414	CbGpPWpGaD
Lithium—GSK3A—Disease—NOS3—chronic obstructive pulmonary disease	0.000153	0.000412	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—TNF—chronic obstructive pulmonary disease	0.000147	0.000396	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ADRB2—chronic obstructive pulmonary disease	0.000145	0.000391	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000143	0.000385	CbGpPWpGaD
Lithium—GSK3A—Innate Immune System—IL6—chronic obstructive pulmonary disease	0.000141	0.000382	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL1B—chronic obstructive pulmonary disease	0.000141	0.00038	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS2—chronic obstructive pulmonary disease	0.00014	0.000379	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—EGFR—chronic obstructive pulmonary disease	0.000136	0.000367	CbGpPWpGaD
Lithium—GSK3B—Adaptive Immune System—EGFR—chronic obstructive pulmonary disease	0.00013	0.000352	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EDN1—chronic obstructive pulmonary disease	0.00013	0.00035	CbGpPWpGaD
Lithium—GSK3B—Developmental Biology—IL6—chronic obstructive pulmonary disease	0.000118	0.000319	CbGpPWpGaD
Lithium—GSK3B—Disease—SERPINE1—chronic obstructive pulmonary disease	0.000118	0.000319	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—ERBB3—chronic obstructive pulmonary disease	0.000118	0.000318	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—HTR2A—chronic obstructive pulmonary disease	0.000113	0.000306	CbGpPWpGaD
Lithium—GSK3B—Disease—NOS3—chronic obstructive pulmonary disease	0.000113	0.000304	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	0.000112	0.000302	CbGpPWpGaD
Lithium—GSK3A—Immune System—EGFR—chronic obstructive pulmonary disease	0.000107	0.000289	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	0.000107	0.000288	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—LEP—chronic obstructive pulmonary disease	0.000105	0.000284	CbGpPWpGaD
Lithium—GSK3B—Innate Immune System—IL6—chronic obstructive pulmonary disease	0.000104	0.000282	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL1B—chronic obstructive pulmonary disease	0.000104	0.000281	CbGpPWpGaD
Lithium—GSK3A—Disease—TGFB1—chronic obstructive pulmonary disease	0.000101	0.000272	CbGpPWpGaD
Lithium—GSK3A—Disease—EGFR—chronic obstructive pulmonary disease	9.89e-05	0.000267	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	9.48e-05	0.000256	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	8.57e-05	0.000231	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—SERPINE1—chronic obstructive pulmonary disease	8.27e-05	0.000223	CbGpPWpGaD
Lithium—GSK3A—Immune System—IL6—chronic obstructive pulmonary disease	8.23e-05	0.000222	CbGpPWpGaD
Lithium—GSK3B—Immune System—EGFR—chronic obstructive pulmonary disease	7.92e-05	0.000214	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—NOS3—chronic obstructive pulmonary disease	7.89e-05	0.000213	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	7.7e-05	0.000208	CbGpPWpGaD
Lithium—GSK3A—Disease—IL6—chronic obstructive pulmonary disease	7.6e-05	0.000205	CbGpPWpGaD
Lithium—GSK3B—Disease—TGFB1—chronic obstructive pulmonary disease	7.45e-05	0.000201	CbGpPWpGaD
Lithium—GSK3B—Disease—EGFR—chronic obstructive pulmonary disease	7.31e-05	0.000197	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	7.06e-05	0.000191	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—CXCL8—chronic obstructive pulmonary disease	7e-05	0.000189	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	6.93e-05	0.000187	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—MMP9—chronic obstructive pulmonary disease	6.33e-05	0.000171	CbGpPWpGaD
Lithium—GSK3B—Immune System—IL6—chronic obstructive pulmonary disease	6.08e-05	0.000164	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—TP53—chronic obstructive pulmonary disease	5.81e-05	0.000157	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—VEGFA—chronic obstructive pulmonary disease	5.69e-05	0.000154	CbGpPWpGaD
Lithium—GSK3B—Disease—IL6—chronic obstructive pulmonary disease	5.62e-05	0.000152	CbGpPWpGaD
Lithium—GSK3A—Signaling Pathways—IL6—chronic obstructive pulmonary disease	5.32e-05	0.000144	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TGFB1—chronic obstructive pulmonary disease	5.22e-05	0.000141	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—EGFR—chronic obstructive pulmonary disease	5.12e-05	0.000138	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—TP53—chronic obstructive pulmonary disease	4.3e-05	0.000116	CbGpPWpGaD
Lithium—GSK3B—Signaling Pathways—IL6—chronic obstructive pulmonary disease	3.93e-05	0.000106	CbGpPWpGaD
